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Background: Although nifekalant hydrochloride (NIF) has been demonstrated to suppress ventricular
tachyarrhythmias, especially electrical storms, the mechanism by which it does so is still unclear. We
examined the effects of NIF on the spatial dispersion of repolarization (SDR) after implantable
cardioverter-deﬁbrillator (ICD) shock.
Methods and Results: In 35 patients with oral amiodarone and β-blocker therapy, and an ICD, we
recorded the 87-lead electrocardiogram during sinus rhythm (CONTROL-1 group) under general
anesthesia, and just after the termination of induced ventricular ﬁbrillation (VF) by ICD shock, with or
without NIF administration. In all recordings, the corrected QT interval (QTc) was measured in each lead.
The dispersion of QTc (QTc-D; maximum QTc minus minimum QTc) was also measured. Compared with
that in the CONTROL-1 group, the QTc-D exhibited signiﬁcant deterioration after ICD shock (61714 and
90719 ms1/2, respectively; po0.05). However, after the termination of induced VF by ICD shock with
NIF administration, the QTc-D did not differ signiﬁcantly from that in the CONTROL-1 group (63720 and
61714 ms1/2, respectively).
Conclusions: NIF suppressed the deterioration of the SDR after ICD shock. This might be one of the
mechanisms by which NIF suppresses recurrence of ventricular tachyarrhythmia just after ICD shock in
patients with oral amiodarone and β-blocker therapy.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The implantable cardioverter-deﬁbrillator (ICD) has dramati-
cally reduced the risk of sudden death in patients with malignant
ventricular tachyarrhythmias [1,2]. However, 10–30% of patients
who have undergone ICD implantation experience “electrical
storms,” in which ventricular tachyarrhythmias occur ≥2 times
within a 24-h period [3]. Patients with severe electrical storm are
known to have a worse prognosis [4].
Some studies have demonstrated that ICD shocks increase the
dispersion of ventricular repolarization [5,6]. The spatial disper-
sion of ventricular repolarization plays a role in the initiation and
maintenance of malignant ventricular tachyarrhythmias, including
electrical storms. The QT dispersion and recovery time dispersion
are assumed to reﬂect the spatial heterogeneity [7,8].t Rhythm Society. Published by Els
+81 6 6646 6808.
.jp (M. Takagi).Few therapeutic options are currently available for controlling
electrical storms. Nifekalant hydrochloride (NIF) is a class III
antiarrhythmic drug that causes dose-dependent prolongation of
the action potential duration in both atrial and ventricular muscle,
mainly by reducing the rapid component of the delayed rectiﬁer
K+ current (Ikr) [9,10]. Several clinical studies have demonstrated
the effectiveness of intravenous NIF for recurrent ventricular
tachyarrhythmias that are resistant to other antiarrhythmic drugs
and ICD shock [11], especially electrical storms [12]. However, little
is known about the electropharmacological basis of the efﬁcacy of
NIF in treating these arrhythmias. Moreover, the effect of NIF on
the spatial dispersion of repolarization (SDR) has not been
reported yet in any clinical study.
In the clinical setting, most patients with electrical storm and
impaired left ventricular function because of structural heart
diseases take oral amiodarone and β-blocker agents. Therefore,
in the present study, we measured the SDR obtained from the 87-
lead body surface-mapping electrocardiogram (ECG), and exam-
ined the effects of NIF on the SDR after ICD shock in patients with
oral amiodarone and β-blocker therapy.evier B.V. All rights reserved.
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Fig. 1. (A) Protocol of this study. The 87-lead body surface ECG was recorded 4 times in all patients [(1)–(4)]: (1) CONTROL-1 group, during sinus rhythm after injection of
propofol; (2) DC group, just after termination of induced VF by ICD shock; (3) CONTROL-2 group, 30 min after ICD shock, before administration of NIF; (4) NIF-DC group, just
after termination of induced VF, after NIF administration by ICD shock. VF, ventricular ﬁbrillation; ICD, implantable cardioverter-deﬁbrillator; NIF, nifekalant hydrochloride.
(B) Plots of the 87 unipolar electrode sites and of the 6 precordial leads (dots). The 87 leads are arranged in a lattice-like pattern, with the exception of 4 leads on both
midaxillary lines (A6, A7, I6, and I7). Leads V1 and V2 of the 12-lead ECG are located between rows 4 and 5 and columns D and E, and between rows 4 and 5 and columns E
and F, respectively, whereas leads V4, V5, and V6 are coincident with G4, H4, and I4, respectively.
Table 1
Patient characteristics.
Men/women (n) 28/7
Age (years) 6579
LVEF (%) 36714
Underlying heart disease, n (%)
Prior MI 15 (43%)
DCM 6 (17%)
HCM 6 (17%)
Sarcoidosis 4 (11%)
HHD 2 (6%)
Valve disease 2 (6％)
Medication, n (%)
Amiodarone+ β-blocker 35 (100%)
LVEF, left ventricular ejection fraction; MI, myocar-
dial infarction; DCM, dilated cardiomyopathy;
HCM, hypertrophic cardiomyopathy; HHD, hyper-
tensive heart disease.
Table 2
Measurements of electrocardiographic parameters in 87-lead ECG.
CONTROL-1 DC CONTROL-2 NIF-DC
HR (bpm) 61710 58710 58711 5177
QRS (ms)
Max 142743 137724 138724 136723
Min 84720 81719 88721 84719
QT (ms)
Max 492747 524744a 501740b 561746a,b,c
Min 438755 434741 455742 491745a,b,c
QTc (ms1/2 )
Max 497736 511744 488734 513734c
Min 443736 416739a 435728 454728b
Dispersion
QRS 62741 58710 5279 53711
QT 5878 93725a 53711b 64717b
QTc 61714 90719a 59714b 63720b
Values are mean7SD; max, maximum value among the 87 leads; min, minimum
value among the 87 leads; Dispersion, max minus min; QT, QT interval; QTc,
corrected QT interval.
a po0.05 vs. CONTROL-1;
b po0.05 vs. DC;
c po0.001 vs. CONTROL-2.
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2.1. Patient population
A total of 35 consecutive patients (28 men and 7 women, mean
age 6677 years) were enrolled in this study between November
2001 and November 2010. All patients underwent ICD implantation
and met all of the following criteria: (1) with structural heart disease
except for arrhythmogenic right ventricular cardiomyopathy;
(2) with clinical documentation of ventricular tachyarrhythmias or
unexplained syncope; and (3) with inducible sustained ventricular
tachyarrhythmias during the electrophysiological study and receiv-
ing antiarrhythmic drugs. Patients were excluded if they had atrial
ﬁbrillation, pacing rhythm, or bundle branch block. In all patients,
predischarge testing of the ICD was performed 1 week after
implantation. This study was approved by the ethical review
committee of our institution. Written informed consent for partici-
pation in this study was obtained from all patients.
2.2. Protocol for ICD testing
The protocol for the ICD testing in this study is presented in
Fig. 1A.
In all patients, ICD testing was performed under intravenous
general anesthesia (propofol), and ventricular ﬁbrillation (VF) was
induced using a right ventricular ICD lead. After 8 pacing cycles with
a cycle length of 400 ms, an electrical shock of 1.2 J was applied on
the top of the T wave. Attempts were made to terminate episodes of
induced VF with the ICD with a 20 J biphasic shock. After a 30-min
interval, NIF was administered as a loading infusion of 0.3 mg/kg for
10 min. VF was then induced using the same protocol, and termina-
tion of VF was attempted with a 20 J biphasic shock. All induced
episodes of VF were successfully terminated by a 20 J biphasic shock.
The 87-lead body surface ECG was recorded between the
propofol injection and the VF induction as a baseline record
(CONTROL-1 group), just after the ICD shock (DC group), 30 min
after the ICD shock and before NIF administration (CONTROL-2
group), and just after the ICD shock with a loading infusion of NIF
(NIF-DC group).
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In all patients, we recorded the 87-lead body surface ECGs in
the supine position, using a VCM-3000 (Fukuda Denshi, Tokyo,
Japan) [13], in which the leads covered the entire thoracic surface
and were arranged in a lattice-like pattern (137 matrix), except
for 4 leads on the midaxillary lines; 59 leads were located on the
anterior chest (columns A–I) and 28 leads on the back (columns
J–M) (Fig. 1B). These 87 unipolar ECGs with Wilson's central terminal
as a reference; the standard 12-lead ECG; and the Frank X, Y, and Z
scalar leads were simultaneously recorded during sinus rhythm.
2.4. Measurements
We visually measured the following parameters in each lead:
the QT interval (QT), deﬁned as the time interval between QRS
onset and the point at which the isoelectric line intersected a
tangential line drawn at the maximal downslope of the positive
T-wave or at the maximal upslope of the negative T-wave. The QT
was measured from all 87-lead ECGs, and corrected for the R–R
interval by using Bazett's method (QTc [corrected QT]: QT/√RR).
When the peak or nadir of the T wave for a lead could not be
detected, that lead was excluded from analysis.
The maximum (max) and minimum (min) QTc values were also
obtained from all 87 leads. As an index of SDR, dispersion of QTc
(QTc-D) was deﬁned as the interval between the max and min
(max minus min) QTc. These measurements were made by
3 cardiologists who were unaware of the clinical ﬁndings in theTable 3
Comparison of QTc-D between IHD and non-IHD.
IHD Non-IHD
n (%) 15 (43) 20 (57)
CONTROL-1 (ms1/2) 62714 6178
DC (ms1/2) 86722 94725
CONTROL-2 (ms1/2) 6079 56715
NIF-DC (ms1/2) 63720 65715
ΔQTc-D(DC–CONTROL-1) (ms1/2) 27719 32727
ΔQTc-D(DC–NIF-DC) (ms1/2) 26716 28721
Values are mean7SD.
IHD, ischemic heart disease; non-IHD, nonischemic heart disease.
ΔQTc-D(DC–CONTROL-1)¼the difference of QTc-D between the DC and CONTROL-1
groups.
ΔQTc-D(DC–NIF-DC)¼the difference of QTc-D between the DC and NIF-DC groups.
Fig. 2. Representative 87-lead ECG obtained in the CONTROL-1 group. The maximal QTc (
anterior chest (F5). The QTc-D was 44 ms1/2. QTc, corrected QT interval; QTc-D, dispersisubjects. When the measured values were not identical, the mean
values of the 3 measurements were calculated. Intra-observer
variability was determined from triplicate measurements.
2.5. Deﬁnition of recurrent ventricular tachyarrhythmias
Patients were prospectively followed during the study period.
We deﬁned recurrent arrhythmias as sustained ventricular tach-
yarrhythmia or VF obtained from the ICD memory. Sustained ven-
tricular tachyarrhythmia was deﬁned as a rate of 4150 beats/min
and treated by ICD using anti-tachycardia pacing or shock therapy.
VF was deﬁned as tachyarrhythmia with a rate of 4200 beats/min
and treated by ICD shock therapy.
2.6. Statistical analysis
Values are mean7SD. Differences in each parameter between
the CONTROL-1, DC, CONTROL-2, and NIF-DC groups were exam-
ined by ANOVA with repeated measures, followed by Scheffé's
multiple comparison test. The Mann-Whitney U-test was used to
compare parameters between 2 factors. Values of po0.05 were
considered signiﬁcant.
Inter-observer and intra-observer variabilities were assessed
according to the Bland and Altman method. Values of po0.05
were taken to indicate signiﬁcant differences.3. Results
3.1. Clinical proﬁle of patients
The characteristics of the patients in this study are presented in
Table 1. The mean left ventricular ejection fraction was relatively
low (36714%). Fifteen patients (43%) had prior myocardial infarc-
tion, whereas the others (57%) had nonischemic heart disease. All
patients were receiving oral amiodarone at a dose of 200 mg/day
and β-blocker agents.
3.2. Eighty-seven-lead ECG ﬁndings
Each ECG parameter was measured in all 37 patients.
Representative ECGs are shown in Figs. 2 and 3. Fig. 2 shows the
87-lead ECG results in the CONTROL-1 group. Fig. 3 shows repre-
sentative ECGs for the max and min QTc in the CONTROL-1 group
(3A), DC group (3B), CONTROL-2 group (3C), and NIF-DC group (3D),max QTc) was located in the left back (J4), and the minimal QTc (min QTc) in the left
on of QTc.
Fig. 3. Representative ECGs in the same patient are shown in each panel. (A) In the CONTROL-1 group, the max QTc, min QTc, and QTc-D were 483 ms1/2, 439 ms1/2, and
44 ms1/2, respectively. (B) After ICD shock, the QTc-D was increased (84 ms1/2). (C) In the CONTROL-2 group, the max QTc, min QTc, and QTc-D were 507 ms1/2, 450 ms1/2, and
57 ms1/2, respectively. (D) After nifekalant administration, the max and min QTc were moderately prolonged in the NIF-DC group (612 and 550 ms1/2, respectively). In
particular, the min QTc in the NIF-DC group was signiﬁcantly prolonged compared with that in the DC group. Abbreviations are as in Figs. 1 and 2.
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patients. Heart rate was signiﬁcantly decreased after NIF adminis-
tration. The QRS duration did not differ among all groups.
Table 2 shows that there were no signiﬁcant differences
between the CONTROL-1 and CONTROL-2 groups in all parameters.
Compared with the CONTROL-1 and CONTROL-2 groups (497736
and 488734 ms1/2), the max QTc was not different in the DC
group (511744 ms1/2) but was signiﬁcantly prolonged in the
NIF-DC group (513734 ms1/2; po0.001) (Fig. 4A). On the otherhand, the min QTc was signiﬁcantly shortened in the DC group
compared with that in the CONTROL-1 group (416739 and
443736 ms1/2, respectively; po0.05). Moreover, the min QTc in
the NIF-DC group was signiﬁcantly prolonged compared with that
in the DC group (454728 and 416739 ms1/2, respectively;
po0.05) (Fig. 4B). Thus, the QTc-D in the DC group was signiﬁ-
cantly increased compared with those in the CONTROL-1, CON-
TROL-2, and NIF-DC groups (90719, 61714, 59714, and
63720 ms1/2, respectively; po0.05) (Fig. 4C).
Max-QTc
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CONTROL-1 DC NIF-DC CONTROL-2
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CONTROL-1 DC NIF-DC CONTROL-2
443 ± 36 416 ± 39 435 ± 28 454 ± 28 (ms1/2)
(ms1/2)
(ms1/2)
(ms1/2)
(ms1/2)
Fig. 4. Comparison of differences between the CONTROL-1, DC, CONTROL-2, and NIF-DC groups in max QTc (A), min QTc (B), and QTc-D (C). Max QTc was mildly prolonged in
the NIF-DC group, although it was not signiﬁcantly different from that in the DC group (A), whereas the min QTc in the DC group was signiﬁcantly shortened compared with
those in the CONTROL-1 and NIF-DC groups (B). Therefore, QTc-D was signiﬁcantly increased in the DC group compared with that in the NIFE-DC group (C). Other
abbreviations are as in Fig. 2.
K. Maeda et al. / Journal of Arrhythmia 30 (2014) 150–1561543.3. Comparison of the effects of SDR between ischemic and
nonischemic heart diseases
Table 3 summarizes the comparison of the QTc-D in patients with
ischemic heart disease (IHD) or those with nonischemic heart disease
(non-IHD). There were no signiﬁcant differences in any parameter
between IHD and non-IHD patients. Concerning the differences in the
QTc-D between the DC and CONTROL groups (ΔQTc-D(DC–CONTROL-1)),
and between the DC and NIF-DC groups (ΔQTc-D(DC–NIF-DC)), there
were no signiﬁcant differences between IHD and non-IHD patients.
Fig. 5 shows the location of the max QTc and min QTc in the 87 leads
in each group. We divided the whole chest surface into 14 areas
(Fig. 5A): right lateral (columns A and B, superior [rows 6 and 7],
middle [rows 4 and 5], and inferior [rows 1–3]), right anterior
(columns C and D, superior, middle, and inferior), left anterior
(columns E–G, superior, middle, and inferior), left lateral (columns H
and I, superior, middle, and inferior), left posterior (columns J and K),
and right posterior (columns L and M). Concerning non-IHD patients,
in the CONTROL group (Fig. 5B), the max QTc and min QTc were
widely located. In the DC group (Fig. 5C), the location of the max QTc
and min QTc became the left anterior and left lateral regions. In the
NIF-DC group (Fig. 5D), the distribution of max QTc and min QTc
became closer than that in the DC group. Concerning IHD patients, in
the CONTROL group, the max QTc was mainly located in the left
anterior, left lateral, and posterior regions. The min QTc was mainly
located in the anterior region. In the DC group, the location of the
max QTc was concentrated on the left anterior and left lateral regions
(middle to superior region). The location of the min QTc spread to the
inferior and right lateral regions. In the NIF-DC group, the location of
the max QTc and min QTc became closer compared with the
DC group.In patients with IHD, we could ﬁnd no relation between the
infarction area and QTc-D.
3.4. Relation between dispersion of repolarization and recurrence
of ventricular tachyarrhythmias
During the study period, ventricular tachyarrhythmias occurred
in 12 of 35 (34%) patients. Five patients (14%) developed electrical
storm. In the CONTROL-1, DC, CONTROL-2, and NIF-DC groups, there
were no signiﬁcant differences in the 87-lead ECG parameters in
patients with or without recurrence of ventricular tachyarrhythmias.
3.5. Inter- and intra-observer variabilities
There were no signiﬁcant differences inter- and intra-observer
variabilities.
4. Discussion
The major ﬁnding of the present study is that administration of
NIF signiﬁcantly suppressed the deterioration of SDR just after ICD
shock. To the best of our knowledge, this is the ﬁrst study to show
that NIF signiﬁcantly reduces the SDR after ICD shock in patients
receiving oral amiodarone and β-blocker agents. A recent study
reported that the SDR after ICD shock played an important role in
the initiation and maintenance of ventricular tachyarrhythmias
[5–7]. We therefore speculate that the reduction in SDR may be
one of the mechanisms by which NIF suppresses the recurrence of
ventricular tachyarrhythmias just after ICD shock in the presence
of oral amiodarone and β-blocker administration.
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Fig. 5. The location of the max QTc and min QTc among the CONTROL, DC, and NIF-DC groups were plotted, and compared between ischemic heart disease (IHD) and
nonischemic heart disease (non-IHD) patients. Columns A and B correspond to the right lateral region. Columns C and D correspond to the right anterior region. Columns E, F,
and G correspond to the left anterior region. Columns H and I correspond to the left lateral region. Columns J and K correspond to the left posterior region, whereas columns
L and M correspond to the right posterior region. We divided the 7 rows into inferior, middle, and superior side (rows 1–3, 4, and 5–7, respectively).
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Some studies have reported that electrical shock produces
different degrees of action potential duration and dispersion of
repolarization [5,6]. In the present study, ICD shock increased the
QTc-D, as has been reported previously [5,6]; however, the
deterioration of QTc-D did not continue for 30 min because there
were no differences in any parameter between the CONTROL-1
and CONTROL-2 groups. NIF is known to block the delayed rectiﬁer
K+ channel, especially the Ikr channel [9,10], which results in a
prolonged action potential duration. The blocking effect of NIF on
the Ikr channel has been reported to occur rapidly, but recovery
from the block is slow [9]. On the other hand, amiodarone has
many effects including blockade of β-adrenergic receptors, the ﬁrst
inward Na+ current, the L-type Ca2+ current, and the fast and slow
components of delayed rectiﬁer potassium current (Ikr and Iks);
especially, long-term treatment of amiodarone reduces Iks.. Several
clinical studies have demonstrated that amiodarone prolongs the
QTc interval and reduces or does not change the QT dispersion
[14–16]. In this study, all patients were taking oral amiodarone
and β-blocker agents. NIF has a reverse use-dependent blocking
action [17]. In addition, an Ikr channel blocker can enhance QTprolongation especially during bradycardia and may cause torsade
de pointes owing to an increase in transmural dispersion of
repolarization [18,19]. The use of NIF and β-blocker may increase
the SDR, but the combination of oral amiodarone and β-blocker
may have relatively little effect on the SDR. Depending on these
basic pharmacological effects, in the clinical setting, most of the
patients with electrical storm and impaired left ventricular func-
tion due to structural heart diseases take oral amiodarone and β-
blocker agents. In our study, NIF prolonged the max and min QTc
after ICD shock. In particular, we found signiﬁcant prolongation of
the min QTc in the NIF-DC group compared with the DC group. On
the other hand, we found that the location of the max and min QTc
became closer in the NIF-DC group compared with the DC group,
which is believed to be a situation that could easily lead to the
progression of reentrant ventricular tachyarrhythmias. We therefore
suggest that the prolongation of the min QTc after NIF administra-
tion may play an important role in reducing the QTc-D in the whole
heart, ever after ICD shock, and that the effect of NIF may occur
before the undesirable situation that progresses reentrant ventri-
cular tachyarrhythmias, and result in the prevention of subsequent
ventricular tachyarrhythmias after ICD shock to some degree, even
with oral amiodarone and β-blocker administration.
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have suggested the possibility of ventricular tachyarrhythmia,
especially torsade de pointes, occurring under conditions of NIF
administration [18,19]. In this study, neither ventricular tachyar-
rhythmia nor torsade de pointes was observed after NIF adminis-
tration despite QTc prolongation. We conﬁrmed that the loading
dose of NIF (0.3 mg kg−1 10 min−1) is safe even for administration
immediately before ICD shock.
Fig. 5 shows that the area of max QTc and min QTc in patients
with non-IHD was located more widely than that in patients with
IHD. One of the reasons for this ﬁnding is that in patients with
non-IHD, the myocardial damage is distributed diffusely, whereas
it has been found to be distributed focally in patients with IHD. We
found no differences in any parameters between IHD and non-IHD
patients, which might be attributable to the small number of
patients examined and/or those taking amiodarone and β-blocker
agents.
4.2. Feasibility of using NIF for the treatment of electrical storms
NIF, a pure K channel blocker, does not have negative inotropic
effects and does not affect cardiac conduction. In addition, it can
only be used intravenously and its half-life is relatively short.
Moreover, NIF has also been reported to decrease the deﬁbrillation
threshold [20]. Although close monitoring of the QT interval
is needed, NIF may be suitable for the suppression of early
recurrence of ventricular tachyarrhythmias just after ICD shock.
4.3. Study limitations
This study has several limitations. First, all patients were
receiving oral amiodarone. Several clinical studies have demon-
strated that amiodarone prolongs the QTc interval and reduces or
does not change the QT dispersion [14–16]. In this study, the QTc in
the CONTROL-1 and CONTROL-2 groups was slightly prolonged.
Oral amiodarone could have modiﬁed the change in ECG para-
meters in the DC and NIF-DC groups. In the clinical setting,
however, most patients with reduced left ventricular function
and frequent episodes of drug-intolerable ventricular tachyar-
rhythmias receive oral amiodarone and/or a β-blocker. Although
we could not show an NIF effect under conditions without oral
antiarrhythmic drugs, our ﬁndings may be applicable to the
clinical setting. Second, we did not ﬁnd a positive correlation
between the dispersion of repolarization and the recurrence of
ventricular tachyarrhythmias. It may be difﬁcult to predict the
recurrence of ventricular tachyarrhythmias including electrical
storms, by using the ECG parameters of repolarization before
and after ICD shock. It may be premature to draw conclusions
with the small number of patients examined, and this may be an
important issue for future research.5. Conclusion
NIF suppressed the deterioration of SDR just after ICD shock.
This might be one of the mechanisms by which NIF suppresses the
recurrence of ventricular arrhythmias just after ICD shock in the
presence of amiodarone and β-blocker treatment.Disclosure
The authors did not receive any ﬁnancial support.Conﬂicts of interest
None.
References
[1] Moss AJ, Hall JW, Cannom DS, et al. Improved survival with an implanted
deﬁbrillator in patients with coronary disease at high risk for ventricular
arrhythmia: multicenter automatic deﬁbrillator implantation trial investiga-
tors. N Engl J Med 1996;335:1933–40.
[2] Zipes DP, Wyse DG, Friedman PL, et al. A comparison of antiarrhythmic-drug
therapy with implantable deﬁbrillators in patients resuscitated from near-fatal
ventricular arrhythmias. N Engl J Med 1997;337:1576–83.
[3] Credner SC, Klingenheben T, Mauss O, et al. Electrical storm in patients with
transvenous implantable cardioverter-deﬁbrillators: incidence, management
and prognostic implications. J Am Coll Cardiol 1998;32:1909–15.
[4] Verma A, Kilicaslan F, Marrouche NF, et al. Prevalence, predictors, and
mortality signiﬁcance of the causative arrhythmia in patients with electrical
storm. J Cardiovasc Electrophysiol 2004;15:1265–70.
[5] Topaloglu S, Aras D, Sahin O, et al. QT dispersion signiﬁcantly increases after
implantable cardioverter-deﬁbrillator shocks. Ann Noninvasive Electrocardiol
2007;12:44–9.
[6] Pang Y, Zhang N, Ren S, et al. High-energy deﬁbrillation increases the
dispersion of regional ventricular repolarization. J Interventional Card Electro-
physiol 2011;32:81–6.
[7] Zabel M, Lichtlen PR, Haverich A, et al. Comparison of ECG variables of dispersion
of ventricular repolarization with direct myocardial repolarization measurements
in the human hearts. J Cardiovasc Electrophysiol 1998;12:1279–84.
[8] Zabel M, Portnoy S, Franz MR. Electrocardiographic indexes of dispersion of
ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol
1995;25:746–52.
[9] Kushida S, Ogura T, Komuro I, et al. Inhibitory effect of the class III
antiarrhythmic drug nifekalant on HERG channels: mode of action. Eur J
Pharmacol 2002;457:19–27.
[10] Yoshioka K, Amino M, Usui K, et al. Nifekalant hydrochloride administration
during cardiopulmonary resuscitation improves the transmural dispersion of
myocardial repolarization experimental study in a canine model of cardio-
pulmonary arrest. Circ J 2006;70:1200–7.
[11] Katoh T, Mitamura H, Matsuda N, et al. Emergency treatment with nifekalant, a
novel class III anti-arrhythmic agent, for life-threatening refractory ventricular
tachyarrhythmias post-marketing special investigation. Circ J 2005;69:1237–43.
[12] Washizuka T, Chinushi M, Watanabe H, et al. Nifekalant hydrochloride
suppresses severe electrical storm in patients with malignant ventricular
tachyarrhythmias. Circ J 2005;69:1508–13.
[13] Anguita M, Alonso-Pulpón L, Arizón JM, et al. Comparison of the effectiveness
of lovastatin therapy for hypercholesterolemia after heart transplantation
between patients with and without pretransplant atherosclerotic coronary
artery disease. Am J Cardiol 1994;74:776–9.
[14] Aiba T, Shimizu W, Inagaki M, et al. Excessive increase in QT interval and
dispersion of repolarization predict recurrent ventricular tachyarrhythmia
after amiodarone. Pacing Clin Electrophysiol 2004;27:901–9.
[15] Meierhenrich R, Helguera ME, Kidwell GA, et al. Inﬂuence of amiodarone on
QT dispersion in patients with life-threatening ventricular arrhythmias and
clinical outcome. Int J Cardiol 1997;60:289–94.
[16] Cui G, Sen L, Sager P, Singh BN, et al. Effects of amiodarone, sematilide, and
sotalol on QT dispersion. Am J Cardiol 1994;74:896–900.
[17] Nakaya H, Uemura H. Electropharmacology of nifekalant, a new class III
antiarrhythmic drug. Cardiovasc Drug Rev 1998;16:133–44.
[18] Ohashi J, Yasuda S, Miyazaki S, et al. Prevention of life-threatening ventricular
tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
J Cardiovasc Pharmacol 2006;48:274–9.
[19] Yusu S, Ikeda T, Mera H, et al. Effect of intravenous nifekalant as a lifesaving
drug for severe ventricular tachyarrhythmias complicating acute coronary
syndrome. Circ J 2009;73:2021–8.
[20] Murakawa Y, Yamashita T, Kanese Y, et al. Can a class III antiarrhythmic drug
improve electrical deﬁbrillation efﬁcacy during ventricular ﬁbrillation? J Am
Coll Cardiol 1997;29:688–92.
